Building a GCT Portfolio - 2021 World Medical Innovation Forum
Virtual
May 19–21, 2021

Building a GCT Portfolio

Building a GCT Portfolio

Thursday, May 20, 2021

12:35 PM – 12:55 PM
Fireside

GCT represents a large and growing market for novel therapeutics that has several segments. These include Cardiovascular Disease, Cancer, Neurological Diseases, Infectious Disease, Ophthalmology, Benign Blood Disorders, and many others; Manufacturing and Supply Chain including CDMO’s and CMO’s; Stem Cells and Regenerative Medicine; Tools and Platforms (viral vectors, nano delivery, gene editing, etc.). Bayer’s pharma business participates in virtually all of these segments. How does a Company like Bayer approach the development of a portfolio in a space as large and as diverse as this one? How does Bayer approach the support of the production infrastructure with unique demands and significant differences from its historical requirements?

Moderator:
Ansbert Gadicke, MD
  • Co-Founder, Managing Director, MPM Capital
Speaker:
Wolfram Carius, PhD
  • EVP, Pharmaceuticals, Head of Cell & Gene Therapy, Bayer AG
  • Q&A

    01:00 PM – 01:15 PM

the Future of Medicine and AI

May 11–13, 2020 | Boston, MA